

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Wagle et al.

SERIAL NUMBER : 09/766,547

FILING DATE : January 19, 2001



EXAMINER : Rei Tsang Shiao

ART UNIT : 1626

FOR : THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF  
DISORDERS ASSOCIATED WITH PROTEIN AGING

Office of Initial Patent Examination's  
Filing Receipt Corrections  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**REQUEST FOR CORRECTED FILING RECEIPT**

1. Applicants request a Corrected Filing Receipt for the above-mentioned patent application. Applicants enclose a copy of the Filing Receipt with the corrections noted thereon in red.

2. There are errors with respect to the following data, which are:

☒ incorrectly entered  
*and/or*

☐ omitted.

**Error in**

**Correct data**

1. ☐ Applicants' name
2. ☐ Applicants' address
3. ☐ Title
4. ☐ Filing Date
5. ☐ Serial Number
6. ☒ Domestic Priority Data

and claims benefit of 60/259,291 dated 12/29/00  
and claims benefit of 60/259,237 dated 1/2/01  
and claims benefit of 60/259,107 dated 12/29/00  
and claims benefit of 60/259,239 dated 1/2/01

7. ☐ Foreign Applications
8. ☐ Other

3. Applicants respectfully request correction of the Domestic Priority Data.
4. Applicants are concurrently filing a Response to Notice of Allowance and Issue Fee Due. Applicants respectfully request issuance of a corrected filing receipt and further request that the face of Issued U.S. Patent reflect the complete and correct domestic priority data as recited herein.
5. Applicants believe that no fee is due. However, the Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to Deposit Account No. 50-0311, Ref. No. 26448-501.

Respectfully submitted,

  
Ivor R. Elrifi, Reg. No. 39,529  
Attorney for Applicants  
c/o MINTZ, LEVIN  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
Customer No. 30623

Dated: June 29, 2005

VIA FACSIMILE (703) 746-9195  
Date of Deposit: June 29, 2005

Attorney Docket No. 26448-501



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Wagle et al.

SERIAL NUMBER : 09/766,547

EXAMINER : Rei Tsang Shiao

FILING DATE : January 19, 2001

ART UNIT : 1626

FOR : THIAZOLE, IMIDAZOLE AND OXAZOLE COMPOUNDS AND TREATMENTS OF  
DISORDERS ASSOCIATED WITH PROTEIN AGING

Office of Initial Patent Examination's  
Filing Receipt Corrections  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

COMMUNICATION

This communication is in response to the Filing Receipt mailed on October 18, 2001, in furtherance to the Request for Corrected Filing Receipt filed June 20, 2002 and in support of the Request for Corrected Filing Receipt filed herewith.

The Filing Receipt mailed on October 18, 2001 indicates that the instant application claims the benefit of, and priority to, the following applications:

U.S. Patent Application 60/176,995 dated December 29, 2000

U.S. Patent Application 60/183,274 dated February 17, 2000

The Filing Receipt mailed on October 18, 2001 fails to recite that the instant application also properly claims the benefit of, and priority to, the following applications:

U.S. Patent Application 60/259,291 dated December 29, 2000

U.S. Patent Application 60/259,237 dated January 2, 2001

U.S. Patent Application 60/259,107 dated December 29, 2000

U.S. Patent Application 60/259,239 dated January 2, 2001.

Applicants submit the instant application (09/766,547) filed January 19, 2001 is entitled to claim priority to these applications.


Applicants note that a Request for Corrected Filing Receipt was filed with the Office of Initial Patent Examination on June 20, 2002 (copy enclosed) requesting addition of the omitted priority applications recited above. Applicants also filed a Preliminary Amendment (copy enclosed) on June 20, 2002 amending the specification to correctly recite the related applications.

Applicants are concurrently filing a Response to Notice of Allowance and Issue Fee Due. Applicants respectfully request the issuance of a corrected filing receipt and further request that the face of Issued U.S. Patent reflect the complete and correct domestic priority data as recited herein.


Applicants believe that no fees are due with this filing. However, the Commissioner is hereby authorized to charge any additional fees that may be due, or credit any overpayment, to Deposit Account No. 50-0311, Attorney Ref. No. 26448-501.

If there are any questions regarding these references, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,

 Matthew Pares Reg No. 50,572  
Ivor R. Elrifi, Reg. No. 39,529  
Attorney for Applicants  
c/o MINTZ, LEVIN  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
Customer No. 30623

Dated: June 29, 2005



COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/766,547	01/19/2001	1614	825	361331-501		25	12

CONFIRMATION NO. 9923

## UPDATED FILING RECEIPT



\*OC00000006927413\*

DECHERT  
P. O. Box 5218  
Princeton, NJ 08543

Date Mailed: 10/18/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Dilip Wagle, New York, NY;  
Sara Vasan, New York, NY;  
John J. Egan, New York, NY;

## Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/176,995 01/19/2000  
AND CLAIMS BENEFIT OF 60/183,274 02/17/2000

and claims benefit of  
60/259,291 dated 12/29/00  
60/259,237 dated 1/2/01  
60/259,107 dated 12/29/00  
and 60/259,239 dated 1/2/01

## Foreign Applications

If Required, Foreign Filing License Granted 03/13/2001

Projected Publication Date: 01/24/2002

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

RECEIVED

OCT 23 2001


## Title

Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging

Preliminary Class

DOCKETED

424



---

**LICENSE FOR FOREIGN FILING UNDER**  
**Title 35, United States Code, Section 184**  
**Title 37, Code of Federal Regulations, 5.11 & 5.15**

**GRANTED**


The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

**NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Wagle, et al.  
Serial No.: 09/766,547 Art Unit: 1614  
Filing Date: January 19, 2001 Examiner: unknown  
For: Thiazole, Imidazole and Oxazole Compounds and Treatments of  
Disorders Associated With Protein Aging  
Docket No. 361331-501

**ATTN: OFFICE OF INITIAL PATENT EXAMINATION  
CUSTOMER SERVICE CENTER**

Commissioner for Patents  
Washington, DC 20231

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on June 20, 2002.

By: \_\_\_\_\_

*Peggy Ferello*

Peggy Ferello

**REQUEST FOR CORRECTED FILING RECEIPT**

1. Attached is a copy of an official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested. The filing receipt also contains the requested changes thereon.
2. There is an error with respect to the following data, which is:  

☐ incorrectly entered  

*and/or*

☒ omitted.

The domestic priority on the Official Filing Receipt should indicate that the application claims priority to the applications as follows:


Application No. 60/176,995, filed 19-January-2000; No. 60/183,274, filed 17-February-2000; No. 60/259,291, filed 29-December-2000; No. 60/259,237, filed 2-January-2001; No. 60/259,107, filed 29-December-2000; and No. 60/259,239, filed 2 January-2001.

Applicant respectfully submits herewith an Application Data Sheet showing the proper domestic priority applications.

3. (A) ☒ The correction(s) is/are not due to any error by applicant and no fee is due.
- (B) ☐ At least one of the above corrections is due to applicant's error and the fee therefor, under 37 C.F.R. 1.19(h), of \$25.00 is paid as follows:
- ☐ Enclosed is Check No. \_\_\_\_\_ in the amount of \$25.00.
- ☐ Charge Account No. 04-0480 for the \$25.00 required fee.


Please charge Account No. 04-0480 for any additional fee required for consideration of this paper, or credit any overpayment to the same account.

Respectfully submitted,

  
\_\_\_\_\_  
Arthur E. Jackson  
Registration No. 34,354

DECHERT  
Princeton Pike Corporate Center  
PO Box 5218  
Princeton, New Jersey 08543-5218  
Tele: (609) 620-3254  
Fax: (609) 620-3259





## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/766,547	01/19/2001	1614	825	361331-501		25	12

CONFIRMATION NO. 9923

## UPDATED FILING RECEIPT



\*OC00000006927413\*

DECHERT  
P. O. Box 5218  
Princeton, NJ 08543

Date Mailed: 10/18/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Dilip Wagle, New York, NY;  
Sara Vasan, New York, NY;  
John J. Egan, New York, NY;

## Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/176,995 01/19/2000  
AND CLAIMS BENEFIT OF 60/183,274 02/17/2000

and claims benefit of 60/259,291 12/29/00

and claims benefit of 60/259,237 1/2/01

## Foreign Applications

and claims benefit of 60/259,107 12/29/00

and claims benefit of 60/259,239 1/2/01

If Required, Foreign Filing License Granted 03/13/2001

Projected Publication Date: 01/24/2002

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

## Title

Thiazole, imidazole and oxazole compounds and treatments of disorders associated with protein aging

Preliminary Class

RECEIVED

OCT 23 2001

DOCKETED



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

In re Wagle, et al.	:	
	:	
Appln. No.: 09/766,547	:	
	:	
Filing Date: January 19, 2001	:	
For: Thiazole, Imidazole and Oxazole	:	AMENDMENT
Compounds and Treatments of	:	
Disorders Associated With	:	
Protein Aging	:	
Reference: 361331-501	:	
	:	
Art Unit: 1614	:	
Examiner: Unknown	:	

---

Commissioner for Patents  
Washington, DC 20231

Applicant respectfully requests, amendment to the specification. No new matter in the disclosure is presented by this material.

**In the Specification:**

Please replace the paragraph beginning at page 1, lines 5 through 10 with the following rewritten paragraph:

This applications claims the priority of the following applications: Application No. 60/176,995, filed 19-January 2000; No. 60/183,274, filed 17-February-2002; No. 60/259,291, filed 29-December-2000; No. 60/259,237, filed 2-January-2001; No. 60/259,107, filed 29-December-2000; and No. 60/259,239, filed 2-January-2001.

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

The version to show changes made for the paragraph at lines 5 through 10 on page 1 is as follows:

This application claims the priority of the following applications: Application No. 60/176,995, filed 19-January-2000; No. 60/183,274, filed 17-February-2000; No. 60/259,291 [60/\_\_\_\_\_], filed 29-December-2000 (~~Attny. Docket No. 361331-501 P/B~~); No. 60/259,237, [60/\_\_\_\_\_] filed 2-January-2001 (~~Attny. Docket No. 361331-501 P/C~~); No. 60/259,107, [60/\_\_\_\_\_] filed 29-December-2000 (~~Attny. Docket No. 361331-511 P~~); and No. 60/259,239, [60/\_\_\_\_\_] filed 2-January-2001 (~~Attny. Docket No. 361331-511 P/A~~).

DOCKET NO. 361331-501  
SERIAL NO. 09/766,547


In light of the above amendment, replacement of the text containing cross-reference to earlier applications for which the subject application claims priority is earnestly solicited.<sup>1</sup>

Respectfully submitted,



Arthur E. Jackson  
Registration No. 34,354

Date: 6/20/2002

 **Dechert**  
Princeton Pike Corporate Center  
PO Box 5218  
Princeton, New Jersey 08543-5218  
Allen Bloom (609) 620-3214  
Arthur E. Jackson (609) 620-3254  
Fax: (609) 620-3259  
Attention: Arthur E. Jackson

---

<sup>1</sup> **FEE DEFICIENCY**

IF ANY ADDITIONAL EXTENSION IS REQUIRED, PLEASE CONSIDER THIS PAPER A PETITION FOR SUCH AN EXTENSION; ANY FEE FOR THE EXTENSION REQUIRED FOR CONSIDERATION OF THIS PAPER BUT NOT ENUMERATED ABOVE OR IN A TRANSMITTAL OR OTHER ASSOCIATED PAPER CAN BE CHARGED TO ACCOUNT NO. 04-0480.

**AND/OR**

IF ANY ADDITIONAL FEE IS REQUIRED FOR CONSIDERATION OF THIS PAPER, PLEASE CHARGE ACCOUNT NO. 04-0480.